PALISADE BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5.85 USD | -8.02% |
|
-5.95% | -33.90% |
| May. 10 | Palisade Bio, Inc. announced that it has received $3.999943 million in funding | CI |
| May. 07 | Palisade Bio, Inc. Appoints Margery Fischbein to Its Board of Directors | CI |
Presentation Operator MessageOperator (Operator)Greetings, and welcome to the Palisade Bio Mer...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.
Calendar
2024-05-21
- Digestive Disease Week Conference
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.36
USD
Average target price
33.75
USD
Spread / Average Target
+430.66%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -33.90% | 5.96M | |
| +41.79% | 50.93B | |
| -0.56% | 42.12B | |
| +49.62% | 42.05B | |
| -7.20% | 29.18B | |
| +12.59% | 26.02B | |
| -21.51% | 18.9B | |
| +6.92% | 13.21B | |
| +24.91% | 12.17B | |
| +29.60% | 12.16B |
- Stock Market
- Equities
- SNCA Stock
- News Palisade Bio, Inc.
- Transcript : Leading BioSciences, Inc., Seneca Biopharma, Inc. - M&A Call
